Estimations of human pituitary gonadotrophins (HPG), total 17-hydroxycorticosteroids, total 17-oxosteroids and oestrogens have been performed in seven hospitalized postmenopausal subjects receiving treatment with the dithiocarbamoylhydrazine derivatives Compound 22365 and Compound 33828 (Imperial Chemical Industries Ltd.).
Both compounds were shown to be inhibitors of pituitary gonadotrophic function as indicated by urinary HPG assays; Compound 33828 was more active in this respect than Compound 22365.
When Compound 22365 was administered to individual subjects at two different dose levels the time taken for urinary HPG levels to return to pretreatment values was longer in the case of the higher dose.
Neither of the compounds studied produced any effect on adrenocortical function as judged by urinary assays of 17-hydroxycorticosteroids, 17-oxosteroids and oestrogens.
Side effects were noted in two of the seven patients studied. In one subject with pre-existing liver damage it was necessary to stop treatment with Compound 22365 because of the development of mild jaundice.
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 21 | 0 | 0 |
| PDF Downloads | 2 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
